Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics’ valuations are broadly in line with industry benchmarks. The company is also being offered at a discount to the average P/E multiple of 64.9x for its listed peers, according to analysts.
Market analysts have recommended subscribing to the issue, noting that Molbio Diagnostics’ valuations are broadly in line with industry benchmarks. The company is also being offered at a discount to the average P/E multiple of 64.9x for its listed peers, according to analysts.
<iframe src="https://hindustansphere.com/embed/cluster/6454097b69eee122a77cb66a198cc20c059c371f" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Molbio Diagnostics IPO opens today: GMP at 15% — Check price band. Should you subscribe?"></iframe>
